Cervical membrane cancer is one of the malignant tumours common in the female reproductive system, mainly in the uterine membrane. It is mostly found in post-menopausal women, where early symptoms are more visible, such as abnormal utero haemorrhage, and therefore more likely to be detected at an early stage. The choice of treatment depends on the stage, classification, physical condition of the patient and the individual ‘ s will. The treatment of uterine membrane cancer will be described in detail below in the areas of surgical treatment, de-treatment, chemotherapy, endocrine treatment and target-oriented treatment.
I. Surgery
Surgery is the most important treatment for uterine membrane cancer, especially for early patients. Not only can tumours be removed through the operation, but it can also provide the basis for subsequent treatment with a clear phasing.
Standard surgery
uterine hysterectomy: Includes hysterectomy and ovarian ovaries on both sides, applicable to most patients.
lymph clean-up: lymph clean-up is also required for patients with higher stratification periods or at risk of lymph nodes transfer.
Cervical lenses or robotic surgery: A relatively advanced method of surgery is that for early patients, the abdominal lenses or robotic surgery is less traumatic and quick to recover.
2. Operation to preserve reproductive function
In the case of young patients who wish to retain their reproductive function and whose cancer is highly differentiated and confined to the uterine membrane, conservative surgery may be considered after drug control, subject to rigorous follow-up and evaluation.
II. Radiotherapy
Demobilization is an important assistive treatment for endomeal cancer, especially for patients with high-risk phased periods or who are unfit for surgery.
1. Post-operative paralysing: Patients with high post-operative pathologies, lymphoma transfer or high-risk pathologies can reduce the risk of relapse.
2. Root treatment: For patients who cannot undergo surgical treatment, it can be used as a cure.
3. Method of release: Includes external exposure (basic pelvic immersion) and close-to-exposure treatment (intra-mortem treatment), depending on the extent and duration of the tumor.
III. Chemical treatment
chemotherapy is applied to patients with advanced or re-emerging uterine membrane cancer, or as a post-operative assistive treatment. Commonly used chemotherapy drugs include violet alcohol, shunpir, carpenter and Dorubystar.
1. Post-operative assisted chemotherapy: highly phased, high-risk patients often need chemotherapy after surgery to prevent cancer cell proliferation or transfer.
2. Joint chemotherapy: a combination of chemotherapy and release applications, especially for partially advanced patients.
3. Monopharmaceutical treatment: Single chemotherapy may be considered to reduce adverse reactions for elderly and infirm or less resistant patients.
IV. Endocrine treatment
The occurrence of uterine membrane cancer is closely related to estrogen overstimulation, especially in patients with hormone-positive endocrinology.
1. Adaptive population: Endocrine treatment is available to patients with advanced, regenerative or hormonal receptors, as well as to early-age patients who retain reproductive function.
2. Drugs commonly used: These include pregnancy hormones (e.g., hydroxyconone, genosterone), aromatic enzyme inhibitors (e.g., curvature) and GnRH agonists.
3. Conservative treatment: Endocrine treatment is an important option for young patients who wish to retain their reproductive function.
V. Target treatment
Target-oriented treatment has been a new direction for endomeal cancer treatment in recent years, especially for patients with advanced or relapse effects. The target-to-drug route prevents the growth of the tumor by inhibiting specific molecular signals.
1. Common target-oriented drugs: including the Bénédération Monopoly, PI3K/AKT for VEGF routes
